Business Context and Reporting Period
This Form 6-K filing by Galapagos NV (now Lakefront Biotherapeutics NV) covers the results of the Annual and Extraordinary Shareholders' Meetings held on April 28, 2026. The filing documents the approval of the 2025 financial accounts, significant changes to the Board of Directors, and a formal change of the company's name to "Lakefront Biotherapeutics," effective May 8, 2026.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the company. It confirms only that shareholders approved the non-consolidated annual accounts for the year ended December 31, 2025, and the allocation of the annual result as proposed by the Board.
Specific financial values disclosed in the filing relate to governance and audit costs:
- Statutory Auditor Remuneration: EUR 495,000 per year (VAT exclusive) for BDO Bedrijfsrevisoren BV.
- Sustainability Reporting Assurance: EUR 50,000 per year (VAT exclusive) for CSRD assurance.
- Director Remuneration (Effective May 1, 2026):
- Chairperson: EUR 110,000 cash + EUR 135,000 equity-based.
- Lead Non-Executive Director: EUR 75,000 cash + EUR 135,000 equity-based.
- Other Non-Executive Directors: EUR 55,000 cash + EUR 135,000 equity-based.
- Committee Chair: Additional EUR 20,000.
- Committee Member: Additional EUR 15,000.
Material Changes
The most significant material change is the rebranding of the company from Galapagos NV to Lakefront Biotherapeutics NV. Additionally, the Board of Directors underwent a substantial restructuring with the appointment of six new directors and the confirmation of several co-opted appointments to replace resigning members. The company also amended its articles of association to require two directors (at least one independent) to jointly represent the company in dealings with third parties.
Guidance, Outlook, and Corporate Actions
The filing does not contain forward-looking financial guidance or management commentary on operational outlook. Key corporate actions approved include:
- Share Buyback Authorization: The Board is authorized to acquire up to 10% of existing shares for a period of five years, at a price within +/- 15% of the closing price on Euronext Brussels.
- Authorized Capital: Renewed authorization for the Board to increase share capital by up to 20% over five years, with the ability to restrict or cancel preferential subscription rights.
- Board Composition Changes:
- Appointed: Henry Gosebruch (Executive, unremunerated), Jane Griffiths (Independent Non-Executive), Dawn Svoronos (Independent Non-Executive), Neil Johnston (Independent Non-Executive), Devang Bhuva (Non-Executive, unremunerated), Paulo Fontoura (Independent Non-Executive), and Gino Santini (Independent Non-Executive).
- Resigned/Replaced: Stoffels IMC BV (Paul Stoffels), Simon Sturge, Peter Guenter, Elisabeth Svanberg, Andrew Dickinson, and Susanne Schaffert.
- Auditor Re-appointment: BDO Bedrijfsrevisoren BV re-appointed for three years for both financial and sustainability reporting assurance.
Investor Verification Checklist
- Verify the effective date of the name change to "Lakefront Biotherapeutics" (May 8, 2026) and its impact on trading symbols and legal documentation.
- Review the full 2025 Annual Report to understand the financial performance and "allocation of the annual result" approved by shareholders.
- Monitor the utilization of the new 10% share buyback authorization and 20% authorized capital increase.
- Confirm the independence status and specific mandates of the newly appointed directors (Griffiths, Svoronos, Johnston, Fontoura, Santini).
- Check for any press releases or subsequent filings detailing the strategic rationale behind the rebranding and board overhaul.